Additionally, multiple clinical trials have demonstrated anlotinib’s potential as a safe and effective candidate when combined with PD-1 inhibitors or EGFR-TKIs, significantly prolonging PFS and overcoming resistance in patients with metastatic NSCLC [33–35]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.